Dianthus Therapeutics, Inc. (DNTH) stock

DNTHNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$92.48+3.18 (+3.56%)

Close on Nov 12, 2026Market cap $5.17BP/E –Yield 0.00%

Dianthus Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Dianthus Therapeutics's price to sales ratio was 231.9× on Oct 31, 2025, against 198.6× a year earlier.

Period	Period end	Value	Change (pts)
2025	Oct 31, 2025	231.9×	+112.6
2024	Dec 31, 2024	119.3×	–

Parsed from the XBRL in Dianthus Therapeutics's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-67 reverse split on Nov 9, 2023
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is DNTH.

Revenue growth-67.3% · median 0.2%

Operating margin-11592.7% · median -6116.0%

Net margin-9927.5% · median -5712.3%

Advertisement
300 × 250

See a number that looks wrong?